Rob Ramsay

Survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A systematic review and discussion of latest controversies.

Michael Flood, Vignesh Narasimhan, Peadar Waters, Robert Ramsay, Michael Michael, Satish Warrier, Alexander Heriot

Journal article  |  2020  |  The Surgeon

INTRODUCTION: Peritoneal metastases confer the worst survival amongst all sites of metastatic colorectal cancer. The adoption of c..

Future directions in advanced penile cancer - mechanisms of carcinogenesis and a search for targeted therapy

Jiasian Teh, Ellen O'Connor, Jonathon O'Brien, Wei Mou Lim, Michael Taylor, Alexander Heriot, Robert Ramsay, Nathan Lawrentschuk

Journal article  |  2020  |  Future Oncology

Penile squamous cell carcinoma (SCC) is a rare and aggressive urological malignancy. Advanced penile SCC requires multimodal manag..

Re-do cytoreductive surgery for peritoneal surface malignancy: Is it worthwhile?

Vignesh Narasimhan, Francis Cheung, Peadar Waters, Oliver Peacock, Satish Warrier, Craig Lynch, Michael Michael, Robert Ramsay, Alexander Heriot

Journal article  |  2020  |  The Surgeon

BACKGROUND AND OBJECTIVES: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) offers selected pati..

Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy

Vignesh Narasimhan, Josephine A Wright, Michael Churchill, Tongtong Wang, Rachele Rosati, Tamsin RM Lannagan, Laura Vrbanac, Anne B Richardson, Hiroki Kobayashi, Timothy Price, Gayle XY Tye, Julie Marker, Peter J Hewett, Michael P Flood, Shalini Pereira, G Adam Whitney, Michael Michael, Jeanne Tie, Siddhartha Mukherjee, Carla Grandori, et al.

Journal article  |  2020  |  Clinical Cancer Research

PURPOSE: Patients with colorectal cancer with peritoneal metastases (CRPMs) have limited treatment options and the lowest colorect..

Outcomes Following Cytoreduction and HIPEC for Pseudomyxoma Peritonei: 10-Year Experience

Vignesh Narasimhan, Kasmira Wilson, Maneka Britto, Satish Warrier, A Craig Lynch, Michael Michael, Jeanne Tie, Tim Akhurst, Catherine Mitchell, Robert Ramsay, Alexander Heriot

Journal article  |  2020  |  Journal of Gastrointestinal Surgery

BACKGROUND: Pseudomyxoma peritonei (PMP) is a rare clinical presentation, with considerable morbidity and mortality if left untrea..

Colorectal peritoneal metastases: pathogenesis, diagnosis and treatment options - an evidence-based update

Vignesh Narasimhan, Geraldine Ooi, Michael Michael, Robert Ramsay, Craig Lynch, Alexander Heriot

Journal article  |  2020  |  ANZ Journal of Surgery

Peritoneal metastases confer the worst survival among all sites in patients with metastatic colorectal cancer. They develop largel..

Targeting the Tumor Microenvironment in Colorectal Peritoneal Metastases

Wim Ceelen, Robert G Ramsay, Vignesh Narasimhan, Alexander G Heriot, Olivier De Wever

Journal article  |  2020  |  Trends in Cancer

Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: a systematic review and meta-analysis

V Narasimhan, S Tan, J Kong, T Pham, M Michael, R Ramsay, S Warrier, A Heriot

Journal article  |  2020  |  Colorectal Disease

BACKGROUND AND AIMS: Peritoneal metastases from colorectal cancer confer the worst survival among all sites of metastases. The ado..

CD8( ) tumor-infiltrating lymphocytes within the primary tumor of patients with synchronous de novo metastatic colorectal carcinoma do not track with survival

Rosemary Millen, Shona Hendry, Vignesh Narasimhan, Rebecca Abbott, Matthew Croxford, Peter Gibbs, Jeanne Tie, Hui-Li Wong, Ian Jones, Suzanne Kosmider, David Byrne, John Zalcberg, Stephen Fox, Jayesh Desai, Kumar Visvanathan, Robert G Ramsay, Ben Tran

Journal article  |  2020  |  Clinical and Translational Immunology

First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427)

Toan Pham, Lloyd Pereira, Sara Roth, Laura Galletta, Emma Link, Tim Akhurst, Ben Solomon, Michael Michael, Phillip Darcy, Shienny Sampurno, Alexander Heriot, Robert Ramsay, Jayesh Desai

Journal article  |  2019  |  Contemporary Clinical Trials Communications

Background: MYB is a transcription factor that is overexpressed in colorectal cancer (CRC) and also a driver mutation in adenoid c..